

Diabetes Mellitus: Classification, Symptoms and Management: A Review

Nisha K*

Department of Life Science, Shri Guru Ram Rai Institute of Technology and Science, Dehradun, Uttarakhand, India

Review Article

Received: 02/09/2016

Accepted: 09/09/2016

Published: 16/09/2016

***Corresponding author:** Nisha Kapruwan, Hemvati Nandan Bahuguna Garhwal University, Department of life science, Shri Guru Ram Rai Institute of Technology and Science, Dehradun, Uttarakhand, India, **Tel:** +91-8126133997; **E-mail:** nishukapruwan12@gmail.com

Keywords: Metabolic disorder, Insulin, Cardiovascular intricacies, Ulceration, Neuropathy, Retinopathy, Stokes, Polyuria, Polydipsia

ABSTRACT

Diabetes mellitus (DM) generally alluded to as diabetes, is a metabolic issue in which there are high glucose levels over a delayed period or of a deformity in insulin emission, insulin activity, or both. Insulin lack thusly prompts endless hyperglycemia with aggravations of starch, fat and protein digestion system. It is the most normal endocrine issue and by the year 2010, it is assessed that more than 200 million individuals worldwide will have DM and 300 million will in this way have the malady by 2025. Diabetes mellitus is exasperated by and related with metabolic confusions that can along these lines lead to untimely demise. This audit investigates diabetes mellitus as far as its authentic viewpoint, biochemical premise, symptoms, prevention and management alongside the future viewpoints.

INTRODUCTION

Diabetes Mellitus (DM) generally alluded to as diabetes, is a metabolic issue in which there are high glucose levels over a delayed period or of a deformity in insulin emission, insulin activity, or both ^[1]. Insulin lack thusly prompts endless hyperglycemia with aggravations of starch, fat and protein digestion system. It is the most normal endocrine issue and by the year 2010, it is assessed that more than 200 million individuals worldwide will have DM and 300 million will in this way have the malady by 2025 ^[2]. As the malady advances tissue or vascular harm results prompting serious diabetic inconveniences, for example, retinopathy, neuropathy, nephropathy, cardiovascular intricacies and ulceration ^[3]. In this way, diabetes covers an extensive variety of heterogeneous maladies. Symptoms of high glucose incorporate continuous pee, expanded thirst, and expanded craving. On the off chance that left untreated, diabetes can bring about numerous complications. Acute difficulties can incorporate diabetic ketoacidosis, nonketotic hyperosmolar trance state, or death ^[4]. Serious long haul intricacies incorporate coronary illness, stroke, unending kidney disappointment, foot ulcers, and harm to the eyes ^[5].

Etymology of Diabetes Mellitus

The word diabetes originates from Latin diabetes, which thusly originates from Ancient Greek, which actually signifies "a passer through; a siphon" ^[6]. Ancient Greek doctor Aretaeus of Cappadocia (fl. first century CE) utilized that word, with the planned signifying "exorbitant release of pee", as the name for the disease. "Diabetes" is initially recorded in English, in the structure diabetes, in a medicinal content composed around 1425 ^[7]. The word mellitus originates from the traditional Latin word mellitus; signifying "mellitus" (i.e. sweetened with honey, nectar sweet) ^[8]. The Latin word originates from mell-, which originates from mel, signifying "honey", and the postfix - itus, whose importance is the same as that of the English addition "- ite" ^[9]. It was Thomas Willis who in 1675 included "mellitus" to "diabetes" as an assignment for the infection, when he saw the pee of a diabetic had a sweet taste (glycosuria). This sweet taste had been seen in pee by the antiquated Greeks, Chinese, Egyptians, Indians, and Persians ^[10].

History of diabetes mellitus

Diabetes was one of the primary diseases described, with an Egyptian original copy from c. 1500 BCE saying "excessively extraordinary exhausting of the urine" [11]. The initially depicted cases are accepted to be of type 1 diabetes. Indian doctors around the same time distinguished the sickness and characterized it as madhumeha or "nectar pee", noticing the pee would pull in ants [12]. The word "diabetes" or "to go through" was initially utilized as a part of 230 BCE by the Greek Apollonius of Memphis [13]. It was viewed as uncommon amid the season of the Roman realm, with Galen remarking he had just seen two cases amid his career. This is perhaps because of the eating regimen and way of life of the people of old, or because the clinical indications were seen amid the advanced phase of the illness [14]. Galen named the diseases "looseness of the bowels of the pee" (diarrhoea urinosa). The soonest surviving work with a point by point reference to diabetes is that of Aretaeus of Cappadocia (second or mid third century CE). He portrayed the manifestations and the course of the illness, which he ascribed to the dampness and coldness, mirroring the convictions of the "Pneumatic School". He conjectured a connection of diabetes with different maladies and he examined differential conclusion from the snakebite which additionally incites exorbitant thirst. His work stayed obscure in the West until 1552, when the main Latin release was distributed in Venice [15-21].

Type 1 and type 2 diabetes were recognized as independent conditions interestingly by the Indian doctors Sushruta and Charaka in 400-500 CE with type 1 connected with youth and type 2 with being overweight [22]. The expression "mellitus" or "from nectar" was included by the Briton John Rolle in the late 1700s to isolate the condition from diabetes insipidus, which is additionally connected with regular urination [23]. Effective treatment was not created until the early part of the twentieth century, when Canadians Frederick Banting and Charles Herbert Best separated and sanitized insulin in 1921 and 1922. This was trailed by the improvement of the long-acting insulin NPH in the 1940s [24].

CLASSIFICATION OF DIABETES

Classification is based on the production of insulin by the pancreas or the cells of the body response properly towards the insulin production [25]. There are three main types of diabetes mellitus:

Type 1 diabetes mellitus

In this type of diabetes pancreas does not produced insulin properly or no insulin is produces by pancreas [26]. It is also known as insulin dependent diabetes mellitus (IDDM) or juvenile diabetes or early onset diabetes. The causes for type 1 diabetes are unknown. It is less common than type 2, generally only 10% of all diabetes case is type 1 [27]. Patients suffering from type 1 diabetes should take insulin injections for rest of their life. They should likewise guarantee appropriate blood-glucose levels via doing consistent blood tests and taking after an uncommon eating routine [28].

Type 2 diabetes mellitus

In type 2 diabetes the body does not create enough insulin to address its own particular issues or cell does not respond properly against the insulin. This is known as insulin resistance [29,30]. Type 2 diabetes is also known as "Non-Insulin-Dependent Diabetes Mellitus" (NIDDM) or "adult-onset diabetes" [31]. It happens in 75 to 90% of all instances of diabetes in UK. Type 2 diabetes as a rule grows steadily after some time. Most people with the condition might be ignorant of their ailment particularly at early stages as there might be no particular side effects [32]. Type 2 diabetes is frequently connected with weight. Corpulence related diabetes is now and then alluded to as development onset diabetes since it is more normal in more seasoned individuals [33]. In numerous early instances of type 2 diabetes treatment might be conceivable by simply eating a solid eating regimen and checking blood glucose levels routinely. In any case, as type 2 diabetes is a dynamic condition in the long run medicines might be required. There are a few gatherings of oral pills that can be taken to control the glucose. In some serious type 2 diabetics insulin infusions might be vital [34] **Figure 1.**




Figure 1. (a) Type 1 diabetes mellitus and (b) Type 2 diabetes mellitus. Source: <http://www.sciencenutshell.com>.

Gestational diabetes

It is the third type of diabetes. This type affects female during pregnancy. A few ladies have large amounts of glucose in their blood, and their bodies can't create enough insulin to transport the greater part of the glucose into their cells, bringing about dynamically rising levels of glucose [35]. Pregnant ladies with gestational diabetes could conceivably have prior type 1 or type 2 diabetes. Much of the time, gestational diabetes creates amid the second trimester of pregnancy (weeks 14-26) and vanishes after the child is conceived. Gestational diabetes can build the danger of wellbeing issues creating in an unborn infant. Consequently it is imperative to identify it early and treat it suitably. Analysis of gestational diabetes is made amid pregnancy. The dominant part of gestational diabetes patients can control their diabetes with activity and eating routine. Between 10% to 20% of them should take some type of blood-glucose-controlling solutions [36-38]. Undiscovered or uncontrolled gestational diabetes can raise the danger of entanglements amid labour **Figure 2**.



Figure 2. Gestational diabetes. Source: commonchronicdiseases.wordpress.com.

COMPLICATION

Diabetes control is imperative to keep a few intense and interminable confusions. Intense entanglements incorporate diabetic ketoacidosis, hyperosmolar unconsciousness, diseases, hypoglycaemic scenes and so forth [39]. A portion of the interminable or long haul confusions incorporate eye, kidney and nerve harm. A few different issues and way of life propensities are in charge of intensifying diabetes. These incorporate smoking, lifted cholesterol levels, weight, hypertension, and absence of exercise [40].

Some of the common complications of diabetes are Weight loss, Heart diseases or ischemic coronary illness (when the blood supply to the heart muscle is decreased), Hypertension (normal in individuals with diabetes), which can bring up the danger of kidney illness, eye issues, heart assault and stroke, Recuperating of wounds or poor wound healing, cuts and sores take any longer to mend, Glaucoma, watering from eyes, diabetic retinopathy, cataracts and some others, Foot and skin complexities, Kidney disorders, Gum sickness, the muscles of the stomach quit working appropriately, Ketoacidosis (a mix of ketosis and acidosis; amassing of ketone bodies and acidity in the blood), Hyperosmolar Hyperglycemic Nonketotic Syndrome (blood glucose levels shoot up too high, and there are no ketones present in the blood or pee), Hypoglycemia, Never damages [41-48].

PATHOGENESIS OF TYPE 1 DIABETES MELLITUS

Type 1 diabetes mellitus is an autoimmune disorder connected with specific annihilation of insulin producing pancreatic β -cells. The onset of diseases shows the end phase of β -cell annihilation proceeding type 1 diabetes mellitus [49]. There are a number of features represent that type 1 diabetes mellitus is an autoimmune disorder:

1. Nearness of immuno-equipped and adornment cells in invaded pancreatic islets.
2. Nearness of islet cell particular autoantibodies.
3. Adjustments of T cell immunoregulation, in specific in CD4+ T cell compartment.
4. Reaction to immunotherapy.
5. Successive event of other organ particular immune system illnesses in influenced people or in their family individuals [50, 51].

The pathogenesis of specific β -cell pulverization inside the islet in type 1 diabetes mellitus is hard to take after because of checked heterogeneity of the pancreatic sores. At the onset of plain hyperglycemia, a blend of pseudoatrophic islets with cells creating glycogen (a cells), somatostatin (d cells) and pancreatic poly-peptide (PP cells), typical islets, and islets containing both b-cells and penetrating lymphocytes and monocytes might be seen [52]. Lymphocytic invasion is discovered just in the islet containing leftover β -cells and is likely that the chronicity with which type 1 diabetes mellitus creates mirrors this heterogeneity of islet injuries. As opposed to this chronicity in the normal history of the sickness, β -cells are quickly devastated when pancreas is transplanted from indistinguishable twin givers into their long term diabetic twin mates without immunosuppression [53]. In these cases, gigantic insulinitis grows quickly with invading T lymphocytes showing an anamnestic immune system response. Likewise, this perception additionally demonstrates that the incessant time course in type 1 diabetes mellitus (however not in a transplanted pancreas) is an outcome of down administrative phenomena part taking in immunopathogenesis of the disorder [54]. Actuation of islet antigen - particular CD4+ T cells show up to be outright essential for the advancement of diabetes in every single creature model of type 1 diabetes mellitus. CD4+ islet particular T-cell clones produced from diabetic NOD mice, when infused into prediabetic or non-diabetes inclined FI mice, affect insulinitis and diabetes. It was additionally reported that CD4+ T cells are adequate to actuate insulinitis while CD8+ T cells add to the seriousness of the harm [55]. These discoveries together with the proof that insulinitis in endless joining versus host infection may happen without CD8+ T cells recommend that CD4+ T cells might be the main immunocompetent cells required in the disease procedure. In any case, it appears that one and only subset of CD4+ T cells are in charge of illness incitement [56].

Alloantigen RT6 in CD4+ cell are not present in diabetes inclined BB rats and seem to ensure AO rats from MLD-STZ incited diabetes. Down-direction of diabetogenic immune system reaction by the spleen cells got from creatures treated with adjuvants could likewise be clarified by CD4+ T cell subsets transaction. Abnormal state of TH1 type cytokines IL-2 and interferon γ are found to connect on the other hand/and to upgrade prompting of immune system diabetes in trial models [57]. The TH-1 type cells, and specifically their item IFN- γ , initiate macrophages. In creature, models of type 1 DM electron minuscule investigations of pancreata appeared that macrophages are the main cell type attacking the islets. In vitro contemplates and contemplates on perfused pancreas recommend that Interleukin 1 (IL-1) and tumor corruption variable (TNF α), two cytokines fundamentally created by macrophages, affect basic changes of β -cells and concealment of their insulin discharging limit [58,59].

In any case, it appears that IL-1 and TNF don't contribute apparently to the cytotoxic action of macrophages. Interferon γ is likewise an effective activator of macrophages for nitric oxide blend [60]. As of late, confirmation has been given demonstrating, that no synthase movement is included in diabetes advancement [61] **Figure 3.**




Figure 3. Flow chart of pathogenesis of type 1 diabetes mellitus.

These information demonstrated, for the first time, that nitric oxide might be a pathogenic variable in autoimmunity and proposed a probability that another class of immunopharmacological operators, prepared to do adjusting nitric oxide emission might be tried in the counteractive action of type 1 diabetes mellitus improvement [62].

PATHOGENESIS OF TYPE 2 DIABETES

Under typical physiological conditions, plasma glucose focuses are kept up inside a restricted extent, regardless of wide changes in free market activity, through a firmly directed and dynamic communication between tissue affectability to insulin (particularly in liver) and insulin discharge [63]. In type 2 diabetes these instruments separate, with the result that the two principle obsessive deformities in type 2 diabetes are weakened insulin discharge through a brokenness of the pancreatic β -cell, and weakened insulin activity through insulin resistance [64]. Type 2 diabetes mellitus has a more prominent hereditary relationship than type 1 diabetes mellitus, the pathogenesis of type 2 diabetes mellitus is portrayed by weakened insulin discharge and insulin resistance as appeared in [65]. The 100% concordance rate in indistinguishable twins is thought to be over-evaluated, due to a choice or reporting inclination. Twin study based upon population in Finland has demonstrated a concordance rate of 40%, and natural impact might be a conceivable purpose behind the higher concordance rate for type 2 diabetes mellitus than for type 1 diabetes mellitus [66]. Type 2 diabetes mellitus influences 1 to 2% of caucasians yet it is much higher in some ethnic gatherings for example, Pima Indians and Arabs and approaches half in South India. This shows hereditary components are more imperative than ecological elements. Aside from development onset diabetes of the youthful (MODY), the method of legacy for type 2 diabetes mellitus is hazy [67]. MODY, acquired as an autosomal predominant quality, may come about because of transformations in glucokinase quality on chromosome 7p. Glucokinase is a key compound of glucose digestion system in beta cells and the liver. MODY is characterized as

hyperglycemia analyzed prior to the age of a quarter century and treatable for over five years without insulin in situations where islet cell antibodies (ICA) are negative and HLA-DR3 and DR4 are heterozygous [68]. MODY is uncommon in Caucasians, not exactly 1%, and more basic in blacks and Indians, more than 10% of diabetics. Unending complexities in MODY were thought to be exceptional however later were observed to be more normal, showing its heterogeneity [69] **Figure 4.**




Figure 4. Pathogenesis of type 2 diabetes characterized by impaired insulin secretion and insulin resistance.

Considering MODY as a separate entity may masquerade its association with specific genetic diseases; and without a definite genetic marker, it should be treated as type 1 diabetes mellitus [70]. Identification of a nonsense mutation in the glucokinase gene and its linkage with MODY was reported for the first time in a French family, implicating a mutation in a gene involved in glucose metabolism in the pathogenesis of type 2 diabetes mellitus [71]. Later, sixteen mutations were identified in 18 MODY families. They included 10 mutations that resulted in an amino acid substitution, 3 that resulted in the synthesis of truncated protein, and 3 that affected RNA processing [72]. Hyperglycemia in these families was usually mild and began in childhood, whereas the hyperglycemia of MODY families without glucokinase mutations usually appeared after puberty. In type 2 diabetes mellitus molecular, with the exemption of MODY, have not been as effective as in type 1 diabetes mellitus. Transformations in the insulin quality lead to the union and emission of strange quality items, prompting what are called insulinopathies. The majorities of the patients with insulinopathies has hyperinsulinemia, acquired in autosomal style, heterozygous for typical and mutant alleles, and ordinarily react to exogenous insulin organization [73].

The relationship of the polymorphic (hypervariable) 5' flanking district of the human insulin quality and type 2 diabetes mellitus is deficient in some populace bunches, demonstrating that it might be one of numerous components in a multifactorial infection [74]. Indeed, even MODY patients have appeared no relationship with this district. It was specified before that there is a solid relationship between HLA-DR3/4 also, type 1 diabetes mellitus [75]. It was likewise reported that such an affiliation is available with type 2 diabetes mellitus, rendering HLA-DR3/4 markers for beta cell demolition in these patients. Pancreatic irregularities in islet secretory cells in type 2 diabetes mellitus are noted in beta, alpha and delta cells of the islets. Surrenders including insulin discharge incorporate relative reduction in basal discharge, diminished first and second periods of insulin reaction, glucose harshness and amino corrosive excessive touchiness of insulin discharge [76]. The number and volume of beta cells are normally diminished to a large portion of the typical, and the alpha cell mass are expanded prompting

hyperglucagonemia [77]. The islets display hyalinization and amyloid testimony, containing islet amyloid polypeptide (IAPP) or amylin. This is a minor secretory peptide of the beta cells discharged alongside insulin and C-peptide, however its part in the pathogenesis of type 2 DM is not well comprehended. This amylin is thought to deliver insulin resistance. IAPP is lessened with movement of type 2 diabetes mellitus. Cozy contact between beta cells and amyloid store in type 2 diabetes mellitus is noted by electron microscopy [78].

Far from the islets in the exocrine pancreas, greasy invasion and diffuse fibrosis are clear. Faulty islet cell capacity is the essential occasion which might be because of an immune system response delivering hyperglycemia in type 2 diabetes mellitus [75]. The insulin receptor quality is situated on chromosome 19 and it encodes a protein having alpha and beta subunits counting the trans membrane space and the tyrosine kinase space. Transformations influencing the insulin receptor quality have been recognized also, their relationship with type 2 diabetes mellitus and type A insulin resistance is perceived [79].

Type A insulin resistance is inherited and type B is an immune system issue. Restriction fragment length polymorphism (RFLP) investigation of the insulin receptor quality, erythrocyte glucose transporter quality, and HLA qualities, were definitely not discovered helpful as hereditary markers for type 2 diabetes mellitus [80]. Insulin resistance is lacking to bring about clear glucose narrow mindedness, yet may assume a critical part in instances of corpulence where there is known disability of insulin activity. Insulin resistance independent from anyone else might be an optional occasion in type 2 diabetes mellitus, since it is likewise found in non-diabetic hefty people Insulin discharge imperfection might be the essential occasion, showing as weakened pulsatile discharge of insulin [81]. Subsequently, hyperglycemia is an inducer and in addition a result of disabled islet cell capacity and insulin resistance. Numerous variables add to the insulin cold-heartedness including obesity and its span, age, absence of activity, expanded dietary fat what's more, diminished filaments and hereditary elements [82].

Fish oil is there to cure insulin resistance in animals, however not in human beings. It has a defensive impact against thrombosis and vasospasm in type 2 diabetes. Insulin resistance in type 2 diabetes mellitus is most certainly not absolutely clear, it might include lessened insulin receptor number, it might be auxiliary to hyperinsulinemia and hyperglycemia, or it might result from lessened tyrosine kinase movement or indeed, even variations from the norm distal to the receptor including glucose transporter proteins through a group of glucose transporter qualities [83,84].

The GLUT2 gene, intimated in liver and pancreatic beta cells, and GLUT4, intimated in skeletal muscle and adipocytes, are solid competitor qualities for the hereditary vulnerability to type 2 diabetes mellitus [85]. Investigation of these two glucose transporter qualities, in expansion to GLUT1, encoding for the cerebrum/erythrocyte glucose transporter, has yielded, in Caucasians, no relationship of any RFLP marker on haplotype with either type 2 diabetes mellitus or obesity [86].

Obesity has hereditary and additionally ecological causes. It strongly affects the advancement of type 2 diabetes mellitus as it is found in Western nations and some ethnic gatherings, for example, Pima Indians. Obesity is more than only a hazard component; it has a causal impact in the improvement of type 2 diabetes mellitus against a hereditary foundation [87].

Type 2 diabetes patients have a trademark shoulder, support truncal obesity. Supplement piece has likewise been observed to be a danger variable for creating type 2 diabetes mellitus, where expanded fat and diminished starch utilization have added to hyperinsulinemia of corpulence [88]. Dietary strands, both solvent and insoluble, enhance type 2 diabetes mellitus. It is additionally found that basic sugars don't specifically bring about diabetes [89]. Lack of micronutrients, for example, chromium also, copper, is observed to be a critical reason for type 2 diabetes mellitus in a minority of cases. Stress has likewise been thought to incite type 2 diabetes mellitus. Really, obesity and over availability of sustenance instead of anxiety are the contributing components to type 2 diabetes mellitus. In this manner, when perpetual change in dietary propensities is set up, a few people ought to be permitted to get away from the "deep rooted" finding of type 2 diabetes mellitus [90].

SIGN AND SYMPTOMS

People can encounter diverse signs and indications of diabetes, and once in a while there might be no signs. A portion of the signs regularly experienced include are Successive pee (polyuria), Unreasonable thirst (polydipsia), Fatigue, Expanded yearning, Weight reduction, Tiredness and weakness, Hyper-ventilation (kussmaul breathing), Absence of interest and concentration, Skin rashes and itching, A shivering sensation or deadness in the hands or feet, Obscured vision, Headache, Successive diseases, Moderate mending wounds, Heaving and stomach torment (frequently mixed up as this season's cold virus) [91,92].

The advancement of type 1 diabetes is normally sudden and sensational while the indications can regularly be mellow or missing in individuals with type 2 diabetes, making this kind of diabetes difficult to distinguish **Table 1**.

Features	Type 1	Type 2
Therapy	Insulin	Weight loss, thiazolidinedione, metformin, insulin
Insulin sensitivity N	Normal	Reduced
Plasma glucagon	High, can be suppressed	High, resistant to suppression
Body mass	Low (wasted) to normal	Obese
Plasma glucose	Increased	Increased
Plasma insulin	Low or absent	Normal to high initially
Age of onset	Usually less than 20 years	Usually greater than 30 years

Table 1. Person with type 1 and type 2 diabetes mellitus shows different clinical characteristic. Source: Guyton and Hall (2006).

ADVANCED RESEARCH ON DIABETES

Diabetes and microRNA

MicroRNAs (miRNAs) assume a critical part in the pathogenesis of sort 2 diabetes (T2D); they direct a few metabolic pathways including insulin discharge, glucose homeostasis, so their potential as biomarkers of determination and visualization has turned out to be progressively valued [93].

The dominant part of the infection related variety recognized by far reaching affiliation concentrates on (GWAS) maps to the non-protein-coding genome. Endeavors to open the practical effect of these variations in this way depend on a comprehension of the procedures required in the control of translation, most especially those which are dynamic in the cells and tissues ensnared in malady pathogenesis [94]. miRNAs, short (22 nucleotides) non-coding RNAs, are thought to assume a key part in the direction of cell capacity through impacts on mRNA destabilization and/or translational suppression. Modified miRNA capacity has been involved in the pathogenesis of a developing number of maladies, including Tourette's disorder and an assortment of malignancies [95]. There is moreover generous confirmation connecting miRNAs to the control of glucose homeostasis. For instance, miR-375 has been reproducibly appeared to be included in the control of glucose-activated insulin discharge in the murine insulin-emitting cell-line MIN6 and different miRNAs (let-7, miR-103 and - 107) impact insulin affectability in rodents [96]. A large number of the variations vigorously connected with sort 2 diabetes (T2D) in GWAS apply their diabetogenic impact through an essential decrease in insulin emission, putting the pancreatic islet, and the insulin-discharging beta-cell specifically, focal point of the audience as far as T2D pathogenesis. Given noteworthy contrasts in islet physiology amongst rodents and people, and with few appropriate human beta-cell lines accessible, the genomic characterization of essential human islet arrangements gives a critical chance to build up the useful comments that can bolster organic induction at T2D affiliation signals [97].

Latest drugs in treating diabetes

The burden of diabetes and its difficulties is expanding around the world. To constraint this pandemic, drugs focusing on various regions of the pathogenesis of diabetes and its impediment are required. Inflammation considers a key part in the common history of diabetes amid the movement from pre-diabetes to diabetes, counting diminished beta cell secretory limit and insulin resistance. Insulin resistance is an essential part of the metabolic

disorder and assumes a part in the pathogenesis of different macro vascular entanglements. Drugs focusing on incendiary pathways speak to a new approach in the treatment of diabetes and its complexities [98,99].

Etanercept

Etanercept (934 amino acids, 150 kilo Dalton) is a dimeric combination protein with an extracellular ligand authoritative space of the Human Tumor Necrosis Factor Receptor (TNFR) connected to the Fc part of human IgG1 [100]. It is created by a recombinant DNA strategy in Chinese Hamster Ovary cells. Barricade of TNF- α receptor has been appeared to diminish insulin resistance in corpulent rats. A trial of etanercept neglected to enhance insulin affectability in subjects with the metabolic disorder in spite of bringing down CRP. This may have been because of the way that the centralization of TNF- α intracellularly is twice that in the extracellular space, and it is the intracellular TNF- α that is mindful for insulin resistance by means of paracrine impacts which were not obstructed by etanercept [101].

Anakinra

Anakinra (153 amino acids, 17.3 kilo Dalton) is a non-glycosylated type of the Human IL-1 Receptor opponent (IL-1Ra) from which it varies just by the expansion of a solitary methionine build up at the amino end. It is created by a recombinant DNA strategy in *E. coli* [102].

IL-1 adds to debilitated insulin emission, diminished cell multiplication, and apoptosis of pancreatic β cells. The IL-1Ra is endogenously created, and its focuses are lessened in the pancreatic islets of patients with T2DM. Anakinra was concentrated on in T2DM what's more, demonstrated guarantee in expanding beta cell secretory capacity, and diminishing glycemia and markers of systemic inflammation. Authoritative conclusions on the conceivable clinical utility of IL-1Ra in the counteractive action of diabetes are anticipated from the vast continuous Canakinumab Antiinflammatory Thrombosis Outcomes Study stage III clinical trial [103]. The study is being directed in more than 40 nations around the globe and is particularly trying whether hindering the genius provocative cytokine IL-1 β with canakinumab, when contrasted with fake treatment, can lessen rates of intermittent myocardial localized necrosis, stroke, and cardiovascular passing among patients with a background marked by myocardial localized necrosis who stay at high hazard due to a persis-inflamtent elevation of the inflammatory biomarker hsCRP (≥ 2 mg/L) [104].

Sirtuin 1

Sirtuin 1 (Sirt1) is a NAD⁺-subordinate HDAC class III deacetylase. A portion of the SIRT1 deacetylation substrates (PGC1 α , FoXo, p53, and the p65 subunit of NF- κ B (10, 41-43 proteins) are focal controllers of cell digestion system, vitality use, irritation and stress reaction pathways in the cell. These might be an extra focus in lessening irritation. Actuation of Sirt1 may have a mitigating part to play in the islets. Sirt1 overexpression forestalls NF- κ B interceded cytokine- prompted β cell harm and its demeanor has been appeared to be lessened in pancreatic islets after cytokine exposure. Nicotinamide mononucleotide, a metabolite that enlarges sirtuin activity, salvages islets from decreased insulin discharge after IL-1 β and TNF- α exposure. ID of the objectives of every class of HDAC in human islets under incendiary conditions will help in the restorative utilization of this developing class of operators [105,106].

Chloroquine

Chloroquine is a feeble base and conveys a positive charge at acidic ph. It is this property of the medication that makes it specifically gather in lysosomes and produce a focus inclination of a high request. This lysosomatotropic activity is in charge of the hepatic maintenance of insulin. Another activity of the medication is diminished corruption of insulin in the muscle tissue [107]. A review study proposed that the utilization of chloroquine to treat rheumatoid joint inflammation is connected with a lower rate of T2DM. Notwithstanding, this study included a particular gathering of patients who required the medication for another sign. Forthcoming investigations of chloroquine are continuous and the outcomes are anticipated [108].

MANAGEMENT OF DIABETES MELLITUS

Diabetes mellitus is a perpetual infection, for which there is no known cure aside from in particular situations. Management focuses on keeping glucose levels as near ordinary, without bringing on low glucose. This can typically be proficient with a solid eating regimen, exercise, weight reduction, and utilization of suitable meds (insulin on account of type 1 diabetes; oral pharmaceuticals, and additionally potentially insulin, in type 2 diabetes) [109]. Finding out about the sickness and effectively taking an interest in the treatment is vital, since entanglements are far less regular and less extreme in individuals who have very much overseen glucose levels. The objective of treatment is an HbA1C level of 6.5%, however ought not to be lower than that, and might be set higher. Attention is additionally paid to other wellbeing issues that may quicken the negative impacts of diabetes. These incorporate smoking, lifted cholesterol levels, stoutness, hypertension, and absence of customary exercise. Specialized footwear is broadly used to decrease the danger of ulceration, or re-ulceration, in at-danger diabetic feet [110]. Working intimately with your specialist, you can deal with your diabetes by concentrating on six key changes in your everyday life.

Practicing good eating habits

Eating great is significant when you have diabetes, since what you eat influences your glucose. No sustenance's are entirely untouchable. Concentrate on eating just as much as your body needs. Eat a lot of vegetables, organic products, and entire grains. Pick non-fat dairy and incline meats. Limit nourishments that are high in sugar and fat. Keep in mind that starches transform into sugar, so watch your carb consumption. Attempt to keep it about the same from feast to dinner ^[111]. This is considerably more imperative on the off chance that you take insulin or medications to control your blood sugars. A sound eating routine incorporates the amount you eat as well as what you eat. Here are a few tips which are used in our daily life avoid saturated fat, Eliminated nourishments with hydrogenated fats or Trans-fat, Pick unsaturated, unsaturated fats rather than soaked and Trans fats, Eat a ton of high-fibre nourishments like entire grain bread, natural products, and vegetables, eat 6 to 8 servings of grains. Rather than all of a sudden and briefly changing your dietary patterns, roll out little and simple improvements that keep going forever ^[112].

Exercising daily

In case you're not moving, begin. You don't need to join an exercise center and do broadly educating. Simply walk or do dynamic computer games. Having a dynamic way of life helps you control your diabetes by cutting down your glucose. It likewise brings down your odds of getting coronary illness. It can help you lose additional pounds and straightforwardness stress. Your objective ought to be 30 minutes of movement that makes you sweat and inhale somewhat harder most days of the week ^[113].

Getting check-up's

In case you're not getting consistent check-ups, now's an ideal opportunity to begin. See your specialist at any rate twice per year. Diabetes raises your danger of coronary illness. So take in your numbers: cholesterol, pulse, and A1C (normal glucose more than 3 months). Get a full eye exam consistently. Visit a foot specialist to check for issues like foot ulcers and nerve harm ^[114].

Overlooking stress

When you're focused on, your glucose levels go up. Furthermore, when you're on edge, you may not deal with your diabetes well. You may neglect to work out, eat right, or take your endorsed drugs. Discover approaches to soothe stress through profound breathing, yoga, or side interests that unwind you ^[115].

Quitting smoking

Diabetes raises your odds of having wellbeing issues like coronary illness, eye malady, stroke, kidney sickness, vein infection, nerve harm, and foot issues. In the event that you smoke, your possibility of getting these issues is much more prominent. Smoking likewise can make it harder to work out ^[116].

Avoiding alcohol

Avoiding excess alcohol may make it easier to control your blood sugar, so if you choose to drink, don't overdo it. The American Diabetes Association advises that women who drink alcohol have no more than one drink a day and men who drink have no more than two. Drinking alcohol can make your blood sugar go too high or too low ^[117]. Check your blood sugar before you drink, and take steps to avoid low blood sugars. If you use insulin or take drugs for your diabetes, eat when you're drinking. Some drinks like wine coolers may be higher in carbs, so take this into account when counting carbs ^[118].

CONCLUSION

In conclusion, the present study supports the hypothesis regarding to diabetes mellitus. Diabetes is a genuine ailment. The body loses its capacity to control the level of sugar in the blood. Patients with diabetes can be taught how to control their diabetes by controlling what they eat, checking their glucose a few times each day, and working out. If not controlled, diabetes can prompt genuine complexities, for example, kidney disappointment, visual deficiency, removals, and even demise. It is simpler to avert diabetes than to treat it. By adopting the above lifestyle changes, people having diabetes lower the risk of upgrading diabetes and its serious complications. A prevention plan can help to decrease the danger and consequence of diabetes and heart disease while helping a healthier lifestyle.

REFERENCES

1. Thangasami SR, et al. Emphasis of Yoga in the -Management of Diabetes. J Diabetes Metab. 2015;6:613.
2. Govindappa M. A Review on Role of Plants extracts and it's Phytochemicals for the Management of Diabetes. J Diabetes Metab. 2015;6:565.

3. Piero NM, et al. In Vivo Antidiabetic Activity and Safety In Rats of Cissampelos pareira Traditionally Used In The Management of Diabetes Mellitus In Embu County, Kenya. *J Drug Metab Toxicol.* 2015;6:184.
4. Baynes HW .Classification, Pathophysiology, Diagnosis and Management of Diabetes Mellitus. *J Diabetes Metab* 2015;6:541.
5. Mohamed MA, et al. Oral Hypoglycemic as Attractive Alternative to Insulin for the Management of Diabetes Mellitus during Pregnancy. *Gynecol Obstet Sunnyvale.* 2014;4:193.
6. Moss CJ and Mathews ST. Thiamin Status and Supplementation in the Management of Diabetes Mellitus and its Vascular Comorbidities. *Vitam Miner.*2013;2:111.
7. Bayramova AN. Gastroenterological Diseases as a Complications of Type 2 Diabetes Mellitus. *J Gastrointest Dig Syst.* 2016;6:442.
8. Tagliente I, et al. Management and Treatment of Type 1 And 2 Diabetes: State of Art. *Gen Med Los Angeles.* 2016;4:259.
9. Mehta K and Chavda P. Beat Diabetes: Are We Ready. *Gen Med Los Angel.* 2016; 4: e108.
10. Mesquita C, et al. Effect of the Endoplasmic Reticulum Stress on Diabetes Mellitus Type 2 in Hypothalamic Cells. *Endocrinol Metab Syndr.* 2016;5:243.
11. Ignacio BA, et al. Diabetes Mellitus and Neuromuscular Blockade: Review. *J Diabetes Metab.* 2016;7:678.
12. Szybinski Z. Primary Prevention of Obesity and Type 2 Diabetes Mellitus. *Epidemiology Sunnyvale.* 2016;6:243.
13. Parveen S and Anjum S. To Investigate Prevalence of Diabetes Type 1 and Type 2 in HCV Infected Individuals. *Epidemiology Sunnyvale.* 2016;6:246.
14. Hines TA and Kumar S. Certified Electronic Health Records and Quality of Health Care in Type II Diabetes Mellitus Patients. *J Health Med Informat.* 2016;7:231.
15. Hayashi A and Sukanuma N. Physical Activity for Gestational Diabetes Mellitus. *Clinics Mother Child Health.* 2016;13:238.
16. Lambadiari V, et al. Short Term, Low Dose Thyroxin Treatment of Euthyroid Patients with Type 2 Diabetes improves Peripheral Blood Flow and Overall Insulin Sensitivity. *J Diabetes Metab.* 2016; 7:677.
17. Wu X, et al. Development of Type-2 Diabetes Mellitus is associated with Low Levels of ApoA1. *J Diabetes Metab.* 2016;7:669.
18. Abdulrhman MA. Honey as a Sole Treatment of Type 2 Diabetes Mellitus. *Endocrinol Metab Syndr.* 2016;5: 232.
19. Wamique M and Ali W. CETP Gene and Its Role in Diabetes Mellitus Type II - A Review. *J Community Med Health.* 2016;6:425.
20. Da Silva E, et al. Diabetes Mellitus and Periodontitis: Molecular Interrelationships. *J Immuno Biol.* 2016;1:e102.
21. Schianca GPC, et al. Searching For Prediabetes before Diabetes. *Gen Med Los Angeles.* 2016;4:237.
22. El-Sappagh S and Elmogy M. A Decision Support System for Diabetes Mellitus Management. *Diabetes Case Rep.* 2016;1:102.
23. Shrivastava SRBL. Physical Inactivity and Development of Diabetes: An Association Worth to be Explored. *Biol Med Aligarh.* 2016;8:e124.
24. Ota Y, et al. Prognostic Impact of Diabetes Mellitus on Colorectal Cancer. *Biol Med Aligarh.* 2016;8:299.

25. Sharma NR and Rao GHR. Diabetes Management: Expectations and Limitations. *J Diabetes Metab.* 2016;7:662.
26. Berezin AE. Impaired Immune Phenotype of Endothelial Cell-derived Micro Particles: The Missing Link between Diabetes-related States and Risk of Cardiovascular Complications?. *J Data Mining Genomics & Proteomics.* 2016;7:195.
27. Piatkiewicz P, et al. Autoimmunity Markers in Patients with Type 2 Diabetes. *J Clin Diabetes Pract.* 2016;1:107.
28. Fitzner KA, et al. State-level Legislative Efforts to Improve Diabetes Care and thereby Mitigate Complications. *J Diabetic Complications Med.* 2016;1:105.
29. Arthur G. Synaptor and Foot Net Bavaria-New Age in Diabetic Foot Survey. *Clin Res Foot Ankle.* 2016;4:e107.
30. Zain M. Association of Family History of Type 2 Diabetes with COMT Gene Polymorphism I/D in Pakistani Population. *J Down Syndr Chr Abnorm.* 2016;2:108.
31. Batra V and Singh G. A Rare Clinical Presentation of Diabetes Mellitus. *Immunochem Immunopathol.* 2016;2:116.
32. Nishimura T, et al. Bilirubin as a New Biomarker of Diabetes and its Microvascular Complications. *Biochem Anal Biochem.* 2016;5:245.
33. Elshennawy TMA. Effect of Gestational Diabetes on Gross Morphology, Histology and Histochemistry of Human Placenta. *Endocrinol Metab Syndr.* 2016;5:227.
34. Bankura B, et al. Inter-patient Variability in Clinical Efficacy of Metformin in Type 2 Diabetes Mellitus Patients in West Bengal, India. *J Metabolic Syndr.* 2016;5:198.
35. Kanungo S, et al. Diabetes Scenario in a Backward Rural District Population of India and Need for Restructuring of Health Care Delivery Services. *Epidemiol.* 2016;6:224.
36. Mullur RS and Ames D. Impact of a 10 minute Seated Yoga Practice in the Management of Diabetes. *J Yoga Phys Ther.* 2016;6:224.
37. Franek E, et al. Leader 8: Type 2 Diabetes Patients: A Comparison of Baseline Characteristics of Eastern and Western European Participants with Established Cardiovascular Disease in the LEADER Trial. *J Diabetes Metab.* 2016;7:646.
38. Kelleni MT. Chamomile Tea Potentials in Prevention and Amelioration of Type 2 Diabetes Mellitus. *J Diabetes Metab.* 2016;7:649.
39. Korczak DJ, et al. The Association of Cortisol Stress Response with Early Adversity and Diabetes Control in Adolescents with Diabetes. *J Depress Anxiety.* 2016;5:217.
40. Constantin C and Ranetti A. Assessment of a Key Message in Newly Diagnosed Type 2 Diabetes Mellitus Patients Considering Their Educational Program. *J Nutr Disorders Ther.* 2016;6:182.
41. Lal R and Basina M. Preconception Care in Pre-gestational Diabetes. *J Women's Health Care.* 2016; 5:e118.
42. Potdar PD and Chaudhari MB. Cellular, Molecular and Therapeutic Advances in Type 2 Diabetes Mellitus. *J Clin Diabetes Pract.* 2016;1:104.
43. Nasrat MA. How Should the World Manage the Challenge of Diabetes Mellitus. *Gen Med Los Angel.* 2016; 4:223.

44. Gangawane AK, et al. Skin Infections in Diabetes: A Review. *J Diabetes Metab.* 2016;7:644.
45. Silvestri F, et al. L225P Mutation of ABCC8 Gene: A Case of Transient Neonatal Diabetes Mellitus with Thrombophilic Predisposition and Epilepsy. *Pediat Therapeut.* 2016;6:274.
46. Fernandez ML. Dietary Cholesterol and Diabetes, What do We know About this Relationship? *J Clin Diabetes Pract.* 2016;1:e102.
47. Roever L and Borges ASR. Mortality in Patients with Type 2 Diabetes: Impact of Age, Glycemic Control, and Renal Complications. *J Diabetes Metab.* 2016;7:e119.
48. Bosek I, et al. Evaluation of Interferon-Gamma in Patients with Type 2 Diabetes and Colorectal Cancer. *J Diabetes Metab.* 2015;7:639.
49. Berezin A. The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus. *Endocrinol Metab Syndr.* 2015;5:1000217.
50. Nicola D and Francesco Z. Future Prospects for the Treatment of Diabetes. *J Clin Diabetes Pract.* 2015;1:e101.
51. Bos AJG, et al. Comparing the Prevalence and Drug Treatment Rates of Diabetes, Hypertension and Dyslipidemia between Japan and Brazil, using 2013 National Health Surveys. *J Clin Diabetes Pract.* 2015;1:103.
52. Wolf E, et al. Symptom and Comorbidity Burden in Chronic Disease: Comparison of HIV-Infection and Diabetes Mellitus in Aging Patients. *J AIDS Clin Res.* 2015;6:527.
53. Marty M, et al. Steatosis, Glycation and Liver Fibrosis in Patients with Diabetes. *J Diabetes Metab.* 2015;6:633.
54. Caldeira EJ. The Diabetes and Allergies. *J Allergy Ther.* 2015;6:e111.
55. Comino E. Access to Health Care for People with Diabetes: Variation in the Use of Primary Care Services for Diabetes Management According to Country of Birth and Geography among Older Australians. *Primary Health Care.* 2015;5:214.
56. Garrido S, et al. Influence of a Regular, Standardized Meal on Lipid Profile of People with Diabetes. *J Mol Genet Med.* 2015;9:182.
57. Gomez-Peralta F, et al. Glycemic Control and Hospital Admission Risk in Type 1 Diabetes is Related to the Use of Carbohydrate Counting and Frequency of Self-Monitoring of Blood Glucose: RSD1 Study. *J Diabetes Metab.* 2015;6:628.
58. Wimalawansa SJ. Preventing Long-Term Complications of Obesity, Type 2 Diabetes, and Metabolic Syndrome: Common Sense Approach *Endocrinol Metab Syndr.* 2015;4:206.
59. Bhargava A, et al. Hypothyroidism: Another Risk Factor for the Development of Diabetes in an Already Vulnerable Asian Indian Population?. *Thyroid Disorders Ther.* 2015;4:e125.
60. Saleem F, et al. Home Medication Review in Improving Patient Medication Adherence and Minimizing Medication Wastage among Type 2 Diabetes Patients. *Health Econ Outcome Res Open Access.* 2015;1:104.
61. Malick R, Belmadani S. Endoplasmic Reticulum Stress and Heart Complication in Diabetes. *J Diabetes Metab.* 2015;6:630.
62. Nansseu JRN. Primary Care Physicians and Diabetes Mellitus Care in Sub-Saharan Africa: Still Very Far Behind the Goals. *Primary Health Care.* 2015;5:208.

63. Singh M and Khan AM. Social Determinants of Diabetes. *J Clin Med Genom.* 2015;3:126.
64. Abdallah HM, et al. Pharmacological Effects of Ethanol Extract of Artemisia Herba Alba in Streptozotocin-induced Type 1 Diabetes Mellitus in Rats. *Biochem Pharmacol Los Angel.* 2015;4:196.
65. Roever L. Pancreatic Steatosis: Is it Related to Obesity, Diabetes Mellitus and Metabolic Syndrome?. *Pancreat Disord Ther.* 2015;5:e139.
66. Pawar K and Thompkinson DK. Multifunctional Ingredient Dietary Supplement for Management of Hyperglycemic and Hypercholesterolemic Therapy of Diabetes. *J Nutr Food Sci.* 2015;5:439.
67. O'Brien KHM, et al. Suicide Risk in Adolescents with Diabetes: A Case Report. *Emerg Med Los Angel.* 2015;5:281.
68. Aponte J. Diabetes Training for Community Health Workers. *J Community Med Health Educ.* 2015;5:378.
69. Prasad S and Cucullo L. Impact of Tobacco Smoking and Type-2 Diabetes Mellitus on Public Health: A Cerebrovascular Perspective. *J Pharmacovigil.* 2015;S2:e003.
70. Roever L and Resende ES. Diabetes and Metabolic Syndrome Can Contribute to Recurrent Vascular Events in Patients with Lacunar Stroke? *J Neurol Disord.* 2015;S1:e101.
71. Kapella-Mshigeni S. Evidence Based Smoking Cessation Intervention Methods for Smokers with Diabetes in Nevada. *J Diabetes Metab.* 2015;6:622.
72. Bharti A, et al. Personalized Diabetes Clinics Revisited. *Biochem Anal Biochem.* 2015;4:e159.
73. Alwahsh SM and Ramadori G. How Does Bariatric Surgery Improve Type II Diabetes? The "Neglected" Importance of the Liver in Clearing Glucose and Insulin from the Portal Blood. *J Obes Weight Loss Ther.* 2015;5:280.
74. Lubomíra F. Weight Loss Pharmacotherapy of Obese Non-Diabetic and Type 2 Diabetic Patients. *J Obes Weight Loss Ther.* 2015;5:277.
75. Zaffani S, et al. Anxiety, Depression and Quality of Life in Italian Youths with Type 1 Diabetes Mellitus. *J Diabetes Metab.* 2015;6:607.
76. Krishnan D, et al. The Impact of Diet Counselling on Type 2 Diabetes Mellitus: An Indian Case Study. *J Diabetes Metab.* 2015;6:610.
77. Bhattacharya PK and Roy A. Tuberculosis and Diabetes Mellitus: A Double Whammy for the Developing Nations. *J Med Diagn Meth.* 2015;4:177.
78. Uwaezuoke SN. Childhood Diabetes Mellitus and the 'Double Burden of Malnutrition': An Emerging Public Health Challenge in Developing Countries. *J Diabetes Metab.* 2015;6:597.
79. Hariprasad MG, et al. Thyroxine: A Putative Neuroprotectant in Diabetes Induced Peripheral Neuropathy in Rats. *J Diabetes Metab.* 2015;6:595.
80. Asma D. Diabetes Positive Living; Highlights from Practice in the Gulf Region. *J Child Adolesc Behav.* 2015;3:226.
81. Tsabang N, et al. Treatment of Diabetes and/or Hypertension Using Medicinal Plants in Cameroon. *Med Aromat Plants.* 2015;S2:003.
82. Galyfos G, et al. Management of Patients with Diabetes Mellitus and Peripheral Artery Disease in the General Practice. *J Gen Practice.* 2015;3:e107.
83. Okoro EO and Oyejola. Aspirin and Diabetes Care in Nigeria: Treatment or Exploitation? *J Clinic Res Bioeth.* 2015;6:227.

84. Nasrat AM, et al. The Challenge of Childhood Diabetes. *Gen Med Los Angel*. 2015; 3: 1000193.
85. Kandaswamy R. A Case of Life-Threatening Diabetic Ketoacidosis Completely Healed Of Diabetes Mellitus with Intent Healing™. *J Diabetes Metab*. 2015;6:587.
86. Mokdad AH, et al. Cost of Diabetes in the Kingdom of Saudi Arabia, 2014. *J Diabetes Metab*. 2015; 6:575.
87. Westfall S, et al. The Gut Microflora and its Metabolites Regulate the Molecular Crosstalk between Diabetes and Neurodegeneration. *J Diabetes Metab*. 2015;6:577.
88. Gupta Y. Double Jeopardy: Dealing with Diabetes and Cancer. *J Diabetes Metab*. 2015;6:578.
89. Kotwal A, et al. Gas-Forming Pyogenic Liver Abscess in a Splenectomized Adult with Diabetes. *J Diabetes Metab*. 2015;6:583.
90. Patra SR and Jahnvi G. An Improvement in Compliance for Foot Care in Persons with Type 2 Diabetes with a Teaching Session. *J Diabetes Metab*. 2011;2:130.
91. Li H, et al. Alcohol Consumption and Risk of Type 2 Diabetes in Mongolian Population, Inner Mongolia, China. *J Diabet Metabol*. 2011;2:116.
92. Mungrue K, et al. Assessment of Weight Loss in the Management of Patients with Type 2 Diabetes Mellitus in Primary Care in Trinidad. *J Diabetes Metab*. 2011;2:120.
93. Fouqueray P, et al. Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of type 2 Diabetes. *J Diabetes Metab*. 2011;2:126.
94. Sripathi V R, et al. Target sites for microRNA expressed in pancreatic islets in Type 2 diabetes mellitus associated genes. *OJB* . 2010;112:224-243.
95. Van de Bunt M, et al. The miRNA Profile of Human Pancreatic Islets and Beta-Cells and Relationship to Type 2 Diabetes Pathogenesis. *PLoS ONE*. 2013;81:e55272.
96. .Kong L., et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. *Acta Diabetol*. 2011;48:61-69.
97. Karolina DS, et al. MicroRNA 144 Impairs Insulin Signaling by Inhibiting the Expression of Insulin Receptor Substrate 1 in Type 2 Diabetes Mellitus. *PLoS ONE*. 2011;68:e22839.
98. Herrera B M, et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. *Diabetologia*. 2010;53:1099-1109.
99. McArthur K, et al. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. *Epub*. 2011;604:1314-1323.
100. David E. Moller .New drug targets for type 2 diabetes and the metabolic syndrome. *Nature*. 2001;414;821-827.
101. Nathan M D, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. *Diabetes Care*. 2006;29:1963-1972.
102. Bowker S L, et. Al. Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin. *Diabetes Care*. 2006;29:54-258.
103. Inzucchi S E and McGuire K D. New Drugs for the Treatment of Diabetes. *Circulation*. 2008;117:574-584
104. Heymann MC and Hofmann SR .Novel Inflammasomes and Type II Diabetes, Intestinal Inflammation and Psoriasis as Newly Inflammasome-Related Diseases. *J Genet Syndr Gene Ther*. 2011;S3:001.
105. Zhao Y. Autoimmunity and Therapeutic Challenges of Type 1 Diabetes. *Translational Medic*. 2011;1:104e.

106. Toy WC, et al. Adiponectin Gene Polymorphisms and Type 2 Diabetes among Singaporean Chinese Adults. *J Diabetes Metab.* 2011 2:152.
107. Bas VN, et al. Evaluation of Factors Affecting Quality of Life in Children with Type 1 Diabetes Mellitus. *J Diabetes Metab.* 2011;2:154.
108. Shivaswamy V, et al. Diabetes, Bone Density, and Fractures. *J Diabetes Metab.* 2011;S1:004.
109. Gioviale MC, et al. Cell Therapy in Type 1 Diabetes. *J Stem Cell Res Ther.* 2011;S2:004.
110. Dodani S and Sharma G .Early Screening for Coronary Artery Disease is Needed in South Asian Indian Immigrants with Type 2 Diabetes. *Endocrinol Metabol Syndrome.* 2011;S5:002.
111. Jenab Y, et al. Diabetic Foot Ulcer is a Significant Predictor of Silent Myocardial Ischemia in Women with Type 2 Diabetes. *J Diabetes Metab.* 2011;2:161.
112. Hotz-Behofsits C. Food and Inflammation: Role of Nutrition in Metabolic Syndrome, Diabetes and Cardiovascular Disease and The Complexity of The Search for A Culprit. *Autacoids.* 2011;1:e104.
113. Srilatha B. High Risk Factors of Cardiovascular Diseases in Type 2 Diabetes. *J Diabetes Metab.* 2011;2:164.
114. Soumya D and Srilatha B. Late Stage Complications of Diabetes and Insulin Resistance. *J Diabetes Metab.* 2011;2:167.
115. Hima Bindu A and Soumya D. Incidence of Diabetes and its Control Measures in AIDS Patients. *J Diabetes Metab.* 2011;2:169.
116. Caporale JE, et al. The Cost of Diabetes Care Programs for Type 2 Diabetes in Argentina: A Probabilistic Sensitivity Analysis. *Primary Health Care: Open Access.* 2011;1:105.
117. Nishant T, et al. Pharmacogenomics- Personalized Treatment of Cancer, Diabetes and Cardiovascular Diseases. *J Pharmacogenomics Pharmacoproteomics.* 2011;2:107.
118. Siddiqui A. Role of Diabetes in prevalence of Tuberculosis. *J Diabetes Metab.* 2011;2:170.